Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Idexx Laboratories (IDXX) due to higher revenues, with a focus on how actual results will compare to estimates to influence stock price [1][2]. Earnings Expectations - Idexx is expected to report quarterly earnings of $3.14 per share, reflecting a year-over-year increase of +12.1%, with revenues projected at $1.07 billion, up 9.8% from the previous year [3]. - The earnings report is scheduled for release on November 3, and better-than-expected results could lead to a stock price increase, while disappointing results may cause a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised 0.46% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Idexx is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.23%, suggesting a bullish outlook on earnings prospects [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Idexx holds a Zacks Rank of 2, enhancing the likelihood of beating the consensus EPS estimate [12]. Historical Performance - Idexx has consistently surpassed consensus EPS estimates, achieving this in the last four quarters, including a +9.67% surprise in the most recent quarter [13][14]. Industry Context - In comparison, Edwards Lifesciences (EW) is expected to report earnings of $0.59 per share, indicating a year-over-year decline of -11.9%, with revenues projected at $1.5 billion, up 11.1% from the previous year [18]. - Edwards Lifesciences has a lower Earnings ESP of -1.22% and a Zacks Rank of 3, making it challenging to predict an earnings beat [19].